Snippet from the article:
Merck (MRK) is experiencing some rough PR issues on its hair-loss drug Propecia following a study that suggests up to 15 percent of men taking the drug might experience some form of sexual dysfunction. For years, the warning label on Propecia has said that only 2 percent of men might experience erectile dysfunction while using the drug, and if users stop taking the pills everything returns to normal
Read the full story — Why Merck’s Hair Loss Drug Could Make Its Income Statement Go, Um, Limp
This article is from a business-oriented site, so it examines more of the bad press and how it may harm Merck’s stock valuation. And with the Propecia patent expiring in a couple years, Merck would probably like to keep the damage control to a minimum. That being said, I believe the study they reference is actually just an analysis of existing studies. Still, articles like this need to be seen by everyone. Knowledge is power.
I tell those patients who have sexual side effects to see me about reducing the dose. The problem of course, is that if you stop the medication the hair loss will continue.